Godavari Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE362C01012
  • NSEID:
  • BSEID: 530317
INR
115.50
-1.45 (-1.24%)
BSENSE

Nov 20

BSE+NSE Vol: 1.53 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 765253,
    "name": "Godavari Drugs",
    "stock_name": "Godavari Drugs",
    "full_name": "Godavari Drugs Ltd",
    "name_url": "stocks-analysis/godavari-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "115.50",
    "chg": -1.45,
    "chgp": "-1.24%",
    "dir": -1,
    "prev_price": "116.95",
    "mcapval": "128.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530317,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE362C01012",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.53 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/godavari-drugs-765253-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Godavari Drugs Gains 1.92%: Valuation Shift and Q2 Results Shape Weekly Moves",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/godavari-drugs-gains-192-valuation-shift-and-q2-results-shape-weekly-moves-4261879",
        "imagepath": "",
        "date": "2026-11-14 15:03:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Nov 09:</strong> Stock opens at Rs.121.00, up 1.09%</p>\n                    <p><strong>Nov 11:</strong> Q2 FY27 results reveal modest growth but margin pressures; stock dips 2.40%</p>\n                    <p><strong>Nov 12:</strong> Continued margin concerns weigh; stock declines 0.55%</p>\n                    <p><strong>Nov 13:</strong> Valuation upgrade sparks 3.87% rally; week closes at Rs.122.00</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.119.70</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div clas..."
      },
      {
        "title": "Godavari Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/godavari-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-4259902",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GodavariDrugsLt_valuationdot_4259902.png",
        "date": "2026-11-13 08:01:05",
        "description": "Godavari Drugs Ltd has seen a marked improvement in its valuation parameters, shifting from an attractive to a very attractive grade, signalling a potential inflection point for investors. Despite a modest day decline of 0.55%, the pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case relative to its peers and historical averages."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-hold-by-marketsmojo-4246247",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GodavariDrugsLt_mojoScore_4246247.png",
        "date": "2026-11-01 10:10:46",
        "description": "Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-hold-by-marketsmojo-4231639",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GodavariDrugsLt_mojoScore_4231639.png",
        "date": "2026-10-21 10:10:56",
        "description": "Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Godavari Drugs Ltd Surges 19.97%: Key Drivers Behind the Rally",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/godavari-drugs-ltd-surges-1997-key-drivers-behind-the-rally-4221305",
        "imagepath": "",
        "date": "2026-10-10 15:03:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>05 Oct:</strong> Valuation shifts signal renewed price attractiveness</p>\n                    <p><strong>08 Oct:</strong> Sharp 9.77% intraday surge on heavy volume</p>\n                    <p><strong>09 Oct:</strong> New 52-week high at Rs.136.95, closing at Rs.140.00 (+8.40%)</p>\n                    <p><strong>09 Oct:</strong> Week closes with a 19.97% gain vs Sensex -0.57%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.116.70</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.140.0..."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-hold-by-marketsmojo-4220714",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GodavariDrugsLt_mojoScore_4220714.png",
        "date": "2026-10-10 10:10:49",
        "description": "Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Godavari Drugs Ltd to 52-Week High of Rs 136.95",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/godavari-drugs-ltd-hits-new-52-week-high-at-rs13695-4220325",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GodavariDrugsLt_priceRelatedfactors_4220325.png",
        "date": "2026-10-09 10:43:45",
        "description": "With a sustained rally that has propelled Godavari Drugs Ltd to a fresh 52-week high of Rs 136.95 on 9 Oct 2026, the stock’s momentum is underpinned by a confluence of bullish technical indicators and consistent price strength over recent sessions."
      },
      {
        "title": "Godavari Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/godavari-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-4213695",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/GodavariDrugsLt_valuationdot_4213695.png",
        "date": "2026-10-05 08:02:27",
        "description": "Godavari Drugs Ltd has witnessed a notable improvement in its valuation parameters, moving from a 'very attractive' to an 'attractive' grade, reflecting a positive shift in price attractiveness amid a challenging pharmaceutical sector backdrop. This upgrade, coupled with robust returns relative to the Sensex, positions the micro-cap pharmaceutical player as a stock worth closer investor attention."
      },
      {
        "title": "Godavari Drugs Ltd Upgraded to Hold on Technical and Valuation Improvements",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/godavari-drugs-ltd-upgraded-to-hold-on-technical-and-valuation-improvements-4207789",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/GodavariDrugsLt_mojoScore_4207789.png",
        "date": "2026-09-29 08:13:06",
        "description": "Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 28 Sep 2026, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The pharmaceutical micro-cap’s enhanced technical trend, attractive valuation, and market-beating returns underpin this revised stance, although fundamental challenges remain."
      }
    ],
    "total": 40,
    "sid": "765253",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/godavari-drugs-765253"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "18-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sushma Kakani",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "17-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Priyanka Jaju",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "17-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Tanushree Kakani",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

18-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sushma Kakani

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

17-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Priyanka Jaju

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

17-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Tanushree Kakani

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available